Abstract
Diabetic foot ulceration remains one of the most common and most serious consequences of diabetes. Persistently high levels of matrix metalloproteases (MMPs) contribute to wound chronicity. Our aim was to assess the concentrations of MMPs and tissue inhibitors of metalloproteinases (TIMPs) in neuropathic and ischemic diabetic foot ulcers by analyzing biopsy samples. In this study, biopsies were taken from 35 diabetic foot ulcers of type 2 diabetes mellitus patients and distinguished in neuropathic (n = 14) or ischemic (n = 21). Zymography assay was utilized for the analysis of MMP-2 and MMP-9 activity. TACE activity was evaluated by a specific fluorimetric assay. mRNA levels of MMPs as well as TIMPs were detected using quantitative real-time polymerase chain reaction. The activity of MMP9 and A Disintegrin and A MetalloProtease Domain 17/TNF-Alpha Converting Enzyme (ADAM17/TACE) was significantly increased in ischemic compared to neuropathic biopsies. No differences were detected between both groups for the mRNA levels of MMPs as well as of ADAMs. However, TIMP3 mRNA expression was decreased in ischemic samples. The combination of increased activity of MMP9 and ADAM17/TACE with decreased concentrations of TIMP-3 mRNA expression in ischemic diabetic foot ulcers compared to neuropathic samples suggests that the increased proteolytic environment may represent a causative factor in the ulcer progression. New treatment strategies for healing diabetic foot ulcers could be directed toward increasing levels of TIMP3.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kalish J, Hamdan A (2010) Management of diabetic foot problems. J Vasc Surg 51:476–486
Mannucci E, Monami M, Lamanna C, Adalsteinsson JE (2012) Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetol 49:307–314
Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H (2002) Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 45:1011–1016
Tarallo S, Beltramo E, Berrone E, Dentelli P, Porta M (2010) Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells. Acta Diabetol 47:105–111
Black RA (2004) TIMP3 checks inflammation. Nat Genet 36:934–935
Qi JH, Ebrahem Q, Moore N et al (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9:407–415
Menghini R, Fiorentino L, Casagrande V, Lauro R, Federici M (2013) The role of ADAM17 in metabolic inflammation. Atherosclerosis 228(2013):12–17
Federici M, Menghini R, Hribal ML et al (2002) Insulin-dependent activation of eNOS is impaired by O-linked-glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106:466–472
Federici M, Hribal ML, Menghini R et al (2005) TIMP-3 deficiency in insulin receptor haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115:3494–3505
Fiorentino L, Vivanti A, Cavalera M et al (2010) Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 51:103–110
Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52:2169–2181
Cardellini M, Menghini R, Martelli E et al (2009) TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 58:2396–2401
Cardellini M, Menghini R, Luzi A et al (2011) Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness. Diabetes 60:3265–3270
Fiorentino L, Cavalera M, Menini S et al (2013) Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay. EMBO Mol Med 5:441–455
Dinh T, Tecilazich F, Kafanas A et al (2012) Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. doi:10.2337/db12-0227
Menghini R, Casagrande V, Menini S et al (2012) TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes 61:454–462
Casagrande V, Menghini R, Menini S et al (2012) Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 32:74–81
Acknowledgments
This manuscript was funded by JDRF RRG 1-2007-665, Fondazione Roma Sostegno alla Ricerca Biomedica 2008, Telethon GGP08065 2008, PRIN 2009FATXW3_002 and Ministero della Salute, Ricerca Finalizzata 2007 and 2008 (all to MF).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by Renato Lauro.
R. Menghini and L. Uccioli equally contributed to this work.
Rights and permissions
About this article
Cite this article
Menghini, R., Uccioli, L., Vainieri, E. et al. Expression of tissue inhibitor of metalloprotease 3 is reduced in ischemic but not neuropathic ulcers from patients with type 2 diabetes mellitus. Acta Diabetol 50, 907–910 (2013). https://doi.org/10.1007/s00592-013-0478-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-013-0478-6